et al., The New England Journal of Medicine , 2023, 10.1056/NEJMoa2301972 Study Objective To evaluate the efficacy, safety, and dose-response effect of Retatrutide a triple GIP, GLP-1, and glucagon receptor agonist in adults with overweight and obesity
In studies, people lost around 11 to 13% of their body weight
Endocrine disrupting chemicals: Impact on human health, wildlife and the environment
At the same time, there seems to be a clawing back of what's out there and then a handing off to pharmaceutical companies to put out compounds for which there are tremendous profit margins
If you're already using something you bought online, bring the vial in and tell us
For those who have trouble breaking through weight plateaus, this might be a breakthrough